Jared Meeker, DO
Pulmonary Disease · Birmingham, ALNPI 1801202114
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 87.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $9,085 and has fallen 95.5% since, to $406 in 2025.
Across 82 payments — averaging $151.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- Pulmonx Corporation$841
- GSK$410
- AstraZeneca$176
- Olympus America Inc.$59
- Regeneron Healthcare Solutions, Inc.$49
- plus $51 from 2 others
What the payments were for
- Travel & lodging$2,66621%
- Food & beverage$2,74322%
- Education$7,00056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 41 | $10,822 |
| Pulmonx Corporation | 7 | $841 |
| GSK | 25 | $410 |
| AstraZeneca | 4 | $176 |
| Olympus America Inc. | 1 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Sanofi | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,409 in reported general payments places this provider in the 80th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 167 | $143,071 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $113,823 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 97 | $74,283 |
| Pirfenidone | 19 | $63,851 |
| Spiriva RespimatTiotropium Bromide | 65 | $60,240 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $46,505 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $45,790 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $40,462 |
| Incruse ElliptaUmeclidinium Bromide | 63 | $27,995 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $20,926 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 28 | $18,177 |
| Spiriva HandihalerTiotropium Bromide | 20 | $15,430 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $12,841 |
| DuleraMometasone/Formoterol | 22 | $7,755 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $7,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $410 | $260,459393 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $176 | $77,522126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$134K
- Amanda DenhamBirmingham$45K
- Bryan GarciaBirmingham$29K
- Steven RoweBirmingham$27K
- Peter MorrisBirmingham$25K
- Russell BeatyBirmingham$24K
- Jay HeideckerBirmingham$21K
- Jennifer TrevorBirmingham$19K
- Jason FainBirmingham$18K
- Jeffrey GarnerBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.